🇺🇸 FDA
Patent

US 9540449

Anti-PCSK9 antibodies with pH-dependent binding characteristics

granted A61KA61K2039/505A61P

Quick answer

US patent 9540449 (Anti-PCSK9 antibodies with pH-dependent binding characteristics) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K2039/505, A61P, A61P3/06